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Abstract
Background: Surveillance of congenital anomalies is important to identify potential 
teratogens. Despite known associations between different anomalies, current surveillance 
methods examine trends within each subgroup separately. We aimed to evaluate whether 
hierarchical statistical methods that combine information from several subgroups 
simultaneously would enhance current surveillance methods using data collected by 
EUROCAT, a European network of population-based congenital anomaly registries. 
Methods: Ten year trends (2003 to 2012) in 18 EUROCAT registries over 11 countries were 
analysed for the following groups of anomalies: neural tube defects, congenital heart 
defects, digestive system and chromosomal anomalies. Hierarchical Poisson regression 
models that combined related subgroups together according to EUROCAT’s hierarchy of 
subgroup coding were applied. Results from hierarchical models were compared to those 
from Poisson models that consider each congenital anomaly separately. 
Results: Hierarchical models gave similar results as those obtained when considering each 
anomaly subgroup in a separate analysis. Hierarchical models that included only around 
three subgroups showed poor convergence and were generally found to be over-
parameterised. Larger sets of anomaly subgroups were found to be too heterogeneous to 
group together in this way. 
Conclusions: There were no substantial differences between independent analyses of each 
subgroup and hierarchical models when using the EUROCAT anomaly subgroups. 
Considering each anomaly separately therefore remains an appropriate method for the 
detection of potential changes in prevalence by surveillance systems. Hierarchical models 
do, however, remain an interesting alternative method of analysis when considering the 
risks of specific exposures in relation to the prevalence of congenital anomalies, which 
could be investigated in other studies. 
Keywords: congenital anomalies, trends, prevalence, hierarchical models 
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Introduction
Congenital anomalies are structural or functional abnormalities that are present at birth. 
They are a leading worldwide cause of fetal and infant death, chronic illness and disability 
in childhood; a diverse group of disorders for which only around 50% can be linked to a 
specific known cause or risk factor (World Health Organization, 2014). Causes of 
congenital anomaly include a wide range of both genetic and environmental factors such 
as maternal age, nutritional status or exposure to certain medications. It is important to 
identify risk factors for congenital anomalies, in particular the early identification of new 
potentially teratogenic exposures. Following the Thalidomide disaster, congenital anomaly 
registries were established worldwide in order to facilitate surveillance and research into 
the causes of birth defects (Khoury and others, 1994; McBride, 1961). A European network 
of such population-based registries, EUROCAT, provides important epidemiologic 
information on congenital anomaly by collecting data on over 1.7 million births from 43 
registries in 23 countries across Europe (EUROCAT, 2016). EUROCAT annually monitors the 
birth prevalence of specific anomalies in order to detect new or continuing trends, 
identifying new potentially teratogenic exposures and evaluating the effectiveness of 
primary prevention policies (Dolk, 2005).  
Surveillance of congenital anomalies is often performed using defined sets of subgroups, 
such as the EUROCAT anomaly subgroups (EUROCAT, 2005). Many of these subgroups 
overlap, for example the congenital heart defects (CHD) subgroup includes further 
subgroups such as ventricular septal defects, atrial septal defects and tetralogy of Fallot 
(ToF). Despite known relationships amongst many of the subgroups, current surveillance 
methods examine trends, clusters or associations between risk factors and anomalies 
within each subgroup separately (EUROCAT, 2015; Loane and others, 2011b). Relevant 
information on relationships between anomalies across the different subgroups is 
therefore not currently being incorporated in surveillance analyses; hence it is possible 
that important associations or trends are not being detected by the current methods. 
Congenital anomaly surveillance methods that combine information from several 
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subgroups simultaneously may enhance the analysis of any particular anomaly by 
considering what is happening in related or similar anomalies. The aim of this paper is to 
evaluate whether hierarchical statistical methods that combine information from several 
subgroups within the same congenital anomaly group simultaneously increase the power to 
detect trends in congenital anomalies. 
Methods
EUROCAT dataset 
This study is based on routinely collected EUROCAT data from 18 full member registries in 
11 European countries: Austria (Styria registry), Belgium (Antwerp and Hainaut), Denmark 
(Odense) France (Paris and Isle de la Reunion), Germany (Saxony-Anhalt) Ireland (Cork & 
Kerry and Dublin), Italy (Tuscany) Netherlands (Northern Netherlands), Spain (Basque 
Country), Switzerland (Vaud) and the UK (East Midlands & South Yorkshire, Northern 
England, Thames Valley, Wales and Wessex). Data was extracted from the EUROmediCAT 
central database in February 2015, including only registries with a total prevalence of all 
anomalies greater than 2% and available data for at least nine years of the ten year period 
from 01 January 2003 to 31 December 2012. All coding was done according to EUROCAT 
guide 1.3 (www.eurocat-network.eu/content/EUROCAT-Guide-1.3.pdf) (EUROCAT, 2005), 
which uses a hierarchy of codes to classify all cases of non-minor congenital anomaly into 
89 EUROCAT anomaly subgroups. EUROCAT anomaly subgroups are grouped in a 
hierarchical structure, with the highest level being the major organ groups, within which 
there are further classes. Spina bifida, for example, is in the neural tube defects (NTD) 
subgroup, which is within the Nervous System group of anomalies. A case may be counted 
only once in each of the lowest level EUROCAT subgroups, but if it has multiple anomalies 
it will be counted in multiple subgroups. Cases with genetic conditions (genetic 
syndromes/ microdeletions, teratogenic syndromes with malformations, or chromosomal 
anomalies) were excluded from all analyses of non-chromosomal anomaly. Data are 
collected for all birth outcomes, including live and still births and terminations of 
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pregnancy for fetal anomaly. Further details regarding the registries, methods of case 
ascertainment and data collection and processing are described elsewhere (Boyd and 
others, 2011; EUROCAT, 2005; Greenlees and others, 2011). 
Statistical Methods 
The most recent ten years of data available were assessed for changes in prevalence for 
the following groups of anomalies: NTDs, autosomal chromosome anomalies, CHDs and 
digestive system anomalies. Poisson regression was used to model prevalence rates for the 
number of congenital anomaly cases each year, with the log total births included as an 
offset to account for the differing population size each year. Estimated average yearly ten 
year trends in prevalence obtained from individual models (separate Poisson models for 
each anomaly subgroup with no information sharing between anomaly subgroups) were 
compared to those obtained from hierarchical models (one Poisson model fitting related 
anomaly subgroups simultaneously with sharing of information between anomaly 
subgroups). For CHDs there are sixteen standard subgroups (EUROCAT, 2005) that have 
previously been grouped using a hierarchical severity ranking according to perinatal 
mortality rates in non-chromosomal cases, formed of three ordered groups from severity I 
(high perinatal mortality) to severity III (low perinatal mortality) (EUROCAT, 2009) (Table 
1). A two level hierarchy that includes the grouping of CHDs by these severity subgroups 
was also considered. A data-level variance component was used to directly model 
potential overdispersion in the data for hierarchical models (Gelman and Hill, 2007). 
Models were also repeated with the inclusion of a term to take account of the random 
effects of registry. All statistical analyses were conducted in R (R Development Core Team, 
2008). Markov Chain Monte Carlo sampling methods were used to obtain estimates of 
variability around the random effects in hierarchical models by using Gibbs sampling 
(Casella and George, 1992) in the Bayesian analysis programme JAGS via the R package 
rjags (Plummer, 2003). Results from hierarchical models are presented as annual 
percentage changes in prevalence and their 95% posterior credible intervals (PCIs), which 
can be thought of as the Bayesian equivalent of 95% confidence intervals (CIs) and where 
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we say there is a 95% probability that the true trend in prevalence lies within this interval. 
If the 95% CI or PCI doesn’t include zero then we consider this a “statistically significant” 
average annual change in prevalence or a “signal”. The resulting estimates are only valid 
if convergence has occurred, which is assessed graphically and by using convergence 
diagnostics in the R package coda (Plummer and others, 2003). Further details on the use 
of the Bayesian hierarchical models in JAGs can be found in the Appendix.
Results
A total of 103,507 cases of congenital anomaly (81,147 cases excluding genetic conditions) 
were available for analysis from a combined population of 4,097,142 births over 18 
registries during the 10 year study period. Trends were assessed in 4,167 NTD, 13,358 
chromosomal, 25,273 CHD and 7,683 digestive system anomaly cases (Table 1). The rarest 
subgroup included in these analyses was the digestive system anomaly annular pancreas, 
with only 57 cases in the combined population over the ten years giving an estimated total 
prevalence of 0.1 cases per 10,000 births. The most common anomaly subgroup was the 
CHD ventricular septal defect, with an estimated total prevalence of almost 28 cases per 
10,000 births (Table 1).  
Models for neural tube defects 
There were no changes in prevalence for any of the NTD subgroups, with estimated 
average annual trends remaining very similar for individual and hierarchical models and 
95% CIs and PCIs including zero (no change) for all estimates (Figure 1). There was some 
“shrinkage” in the estimates towards the group mean in the hierarchical model, in 
particular for encephalocele, although this estimated trend was not significant in either 
model. 
Models for chromosomal anomalies 
In individual models, an increasing trend of 1.7% (95% CI: 0.7% to 2.6%) and 1.8% (95% CI: 
0.4% to 3.1%) per year on average was observed for Down and Edwards syndrome, 
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respectively (Figure 2), but there was no significant change in prevalence of Patau 
syndrome. Trends in prevalence were similar when combining the three anomalies 
together in a hierarchical model; the estimated trend for Patau syndrome increased 
slightly towards the average of the three trends but the 95% PCI still included zero (Figure 
2). 
Models for congenital heart defects 
Of all cases with CHD, 85.5% were counted in one of the three EUROCAT severity groups 
for CHDs, excluding those with patent ductus arteriosus in term infants as well as a 
number of other CHDs that are not assigned a specific subgroup code according to 
EUROCAT’s coding hierarchy. In individual models, decreasing trends for atrial septal 
defect (ASD) and pulmonary valve stenosis (PVS), and an increasing trend for ToF were 
observed (Figure 3). When using a hierarchical model that combined all CHDs (Figure 3), 
the estimated trends for PVS and ToF attenuated towards the null. The only significant 
change in prevalence in a hierarchical model was for ASD, which attenuated slightly to 
3.0% on average from the estimated 4.1% in an individual model. Average annual changes 
in prevalence for the other CHD subgroups were a mix of increasing and decreasing trends, 
none of which were statistically significant in either model. When including severity 
subgroup as an additional level in a hierarchical model for CHDs (Figure 3), the trends for 
ASD and PVS remained significant, with estimated average changes in prevalence very 
similar to those obtained in individual models. The increasing trend for ToF was not 
statistically significant when grouping all CHDs together, whether including the severity 
grouping or not. 
Models for digestive system anomalies 
There were no significant trends in prevalence for any of the digestive system subgroups 
for individual or hierarchical models (Figure 4), with estimated trends in the hierarchical 
model generally attenuating towards the mean of the estimated trends across the eight 
subgroups, which was again close to the null value of no trend. Subgroups that were less 
precisely estimated were more affected by the information in other subgroups, giving 
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more marked differences in estimated trends in the less common anomalies for individual 
models compared to a hierarchical model. 
Model assessment for hierarchical models 
Parameters for hierarchical models that included a reasonable number of subgroups (i.e. 
eight or more for the digestive system anomalies) displayed good convergence. 
Hierarchical models for smaller groups of anomalies (e.g. models for NTDs and autosomal 
anomalies including only three subgroups) showed poor convergence due to over 
parameterisation in the model. Further details on model diagnostics for hierarchical 
models are given in the appendix. 
Including a registry effect 
All models were repeated with the inclusion of a random effect for registry to assess the 
effect of accounting for differences at the registry level. The estimated trends in 
prevalence of each anomaly subgroup remained very similar to those described above 
when including the effect of registry for all models (data not shown). Hierarchical models 
that included a registry effect, in particular those with only a small number of subgroups, 
demonstrated an overall lack of convergence. 
Discussion
For all examples of congenital anomaly subgroups considered in these analyses, estimated 
trends in prevalence were similar whether considering anomalies separately (individual 
models) or together (hierarchical model). Identified trends were consistent with other 
studies. Increasing trends in chromosomal anomalies were observed, which are known to 
be due to maternal age and changes in prenatal screening practices (Cocchi and others, 
2010; Loane and others, 2013). NTD prevalence remained stable in EUROCAT registries, as 
has been observed elsewhere (Botto and others, 2006; Khoshnood and others, 2015). This 
might be explained by the lack of folic acid fortification in Europe and poor uptake of folic 
acid supplementation; in the UK, for example, under 30% of women took folic acid prior to 
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their pregnancy in 2011–2012 (Bestwick and others, 2014). Prevalence in three of the 
digestive system anomaly subgroups was found to be significantly increasing in the latest 
EUROCAT statistical monitoring report (EUROCAT, 2015). A similar estimated increase in 
prevalence in these three subgroups was observed here, although these trends did not 
reach statistical significance in independent models due to the smaller number of 
registries included. Increases in the prevalence of the CHDs single ventricle (severity 
group I), ToF and atrioventricular septal defect (severity group II) were consistent with 
previous findings (EUROCAT, 2015). Estimated decreases in prevalence of ASD and PVS, 
however, were not consistent with those observed in other studies, where either no 
significant changes or increasing trends have been observed (EUROCAT, 2015; van der 
Linde and others, 2011). Published prevalence estimates in CHDs are known to vary 
substantially due to differing definitions of cases across studies, and it is likely that the 
differences in estimated trends here reflect changes in reporting for these anomalies (in 
recent years EUROCAT have focused on only reporting ASD cases that have been confirmed 
after 6 months of age) or differing prenatal screening practices in this particular set of 
registries (Baardman and others, 2014; Garne and others, 2012; Hoffman and Kaplan, 
2002). 
Hierarchical models have proven useful in the field of pharmacovigilance, where they have 
been used in the detection of potential adverse drug reactions (Berry and Berry, 2004; 
Crooks and others, 2012; Xia and others, 2011). Natural hierarchies in drug and adverse 
event coding have been used to group similar drugs or adverse events together, such that 
models for each drug-adverse event combination incorporate information from analyses of 
other similar drugs and adverse events (Prieto-Merino and others, 2011). In this paper, the 
same rationale was applied to congenital anomalies; however, the situation here was 
different compared to that for adverse drug reactions, where the hierarchical 
classification systems may provide more natural hierarchies than the grouping of 
anomalies according to the defined subgroups. Indeed, the EUROCAT subgroup coding 
hierarchy provides sets of anomalies that are too heterogeneous in practice to be grouped 
together when analysing changes in prevalence. This is because the “shrinkage”, a key 
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feature of hierarchical models (Gelman and Hill, 2007) whereby the estimated trend for 
each subgroup is influenced towards the average trend over all subgroups in the model, 
will largely pull estimates towards the null if there is a mixture of increasing and 
decreasing trends, as was the case for CHD and digestive anomalies. It is possible, 
therefore, that potential changes in prevalence in analyses of groups of anomalies such as 
these could actually be masked by hierarchical models. On the other hand, this shrinkage 
can help control estimates based on small counts by including information from the rest of 
the group. Moreover, this can be thought of as a natural “penalisation” considering that a 
hierarchical model is simultaneously looking for changes in prevalence in numerous 
subgroups, compared to individual models where this multiple testing aspect is not taken 
into account (and a number of false positive results are therefore likely). For a group 
where the mean trend across subgroups is close to the null, this penalisation will mean 
that the estimated trend is no longer a “signal” in the hierarchical model, for example as 
seen for the CHD ToF in severity group II (Figure 3). For a group where the mean trend is 
not so close to the null, however, this penalisation might actually lead to an increase in 
the strength and precision of a signal, for example for ASD in severity group III (Figure 3). 
Furthermore, the same signal might be reduced or enhanced depending on which grouping 
is used; for example, the trend in PVS is attenuated if considering all CHD groups together 
but maintained if also including the severity grouping in the hierarchical model (Figure 3). 
This highlights how the posterior distribution is sensitive to the prior information, which 
here is the way the groups have been defined. 
EUROCAT subgroups that were considered to be related, for example aetiologically similar 
or in the same organ system class, were still found to vary considerably in terms of their 
differing proportional yearly changes in prevalence. It is well known (Gelman and Hill, 
2007; Greenland, 2000), and has been seen here in the case of NTDs and autosomal 
trisomy groups of anomalies,  that a random effects model with only three levels for the 
random effect parameter does not perform well, with such models showing poor 
convergence and over-parameterisation. There may be other larger groups of anomalies 
that are similar enough to be analysed together that were not considered here, and in fact 
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there are known relationships between anomalies that lie within different groups of the 
EUROCAT hierarchy. In addition to NTDs, for example, there are a number of other 
anomalies across different body systems that are known to be sensitive to folate levels 
during pregnancy, including CHDs, clefts and limb reduction defects (Wilson and others, 
2015). If there was evidence that folate levels had been increasing in Europe, then it 
would have been useful to have analysed all these anomalies as a hierarchical model. 
However, from examining the NTDs alone here and in other studies, no such change has 
occurred in Europe and hence such models were not further investigated. Similarly, 
EUROCAT now includes a VATER/VACTERL association subgroup that comprises anomalies of 
the vertebra, anal atresia, CHDs, trachea-esophageal fistula, esophageal atresia, radial 
anomaly and limb defect, which are known to occur together more frequently than 
expected by chance. However, the heterogeneity of trends in just the CHD component of 
this subgroup indicates that hierarchical models are not likely to add any useful 
information to such an analysis. When examining congenital anomaly prevalence there are 
many factors that are likely to have an influence, such as reporting, case ascertainment or 
screening practices. Hierarchical models might be more relevant, then, when considering 
the risks of specific exposures in relation to prevalence of congenital anomalies. It would 
therefore be worthwhile investigating the application of hierarchical models in such 
situations, for example when looking at the risk of medications taken during the first 
trimester of pregnancy. 
Strengths and limitations of this study 
EUROCAT registries collect data that is ascertained from multiple sources and includes 
information on all major structural congenital and chromosomal anomalies (Boyd and 
others, 2011; Loane and others, 2011a), providing high quality population-based data 
across multiple European countries and allowing the inclusion of a large number of 
congenital anomaly cases covering over four million births over ten years for this study. 
EUROCAT registries include information on cases of prenatal diagnosis followed by 
termination of pregnancy, enabling the inclusion of cases that would otherwise have gone 
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undiagnosed, or unreported amongst spontaneous abortions or stillbirths. One potential 
limitation of this study is that it was not possible to include data from all of the EUROCAT 
member registries in these analyses, hence some trends that were seen in the latest 
statistical monitoring report did not reach statistical significance here, likely due to the 
smaller sample sizes included. However, it does not seem likely that increasing the sample 
size would have improved the performance of hierarchical models. 
Conclusions 
In summary, the hierarchical models considered here demonstrated that sharing 
information between subgroups of anomalies can provide a sensible “penalisation”, 
helping to avoid false positive signals by shrinking the estimated trends towards the null 
when there is no evidence of other trends in the rest of the group, whilst maintaining 
signals of changes in prevalence when there are others in the group. Using the EUROCAT 
hierarchy of anomaly subgroups, however, presented no substantial differences between 
the independent analyses of each subgroup and hierarchical models. When using EUROCAT 
subgroups for analysis, therefore, considering each congenital anomaly separately remains 
an appropriate method for the detection of potential changes in prevalence by relevant 
surveillance systems. Hierarchical models do, however, remain an interesting and 
potentially useful alternative method of analysis when considering the risks of specific 
exposures in relation to the prevalence of congenital anomalies, and this could be 
investigated in other studies. 
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Table and figure legends
Table 1. Total prevalence of selected groups and subgroups of congenital anomalies per 
10,000 births, using data covering 4,097,142 births from 18 EUROCAT registries, 2003 to 
2012. 
Figure 1. Estimated average annual trends in prevalence of neural tube defects with 95% 
Posterior Credibility Intervals.   
Figure 2. Estimated average annual trends in prevalence of chromosomal anomaly 
subgroups with 95% Posterior Credibility Intervals.   
Figure 3. Estimated average annual trends in prevalence of congenital heart defect 
subgroups with 95% Posterior Credibility Intervals.   
Figure 4. Estimated average annual trends in prevalence of digestive system subgroups 
with 95% Posterior Credibility Intervals.  
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